Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout

Clinical and Experimental Nephrology

Volumn 18, Issue 6, 2014, Pages 876-884

  Hosoya, Tatsuo ^a   Ohno, Iwao ^a   Nomura, Shinsuke ^b   Hisatome, Ichiro ^c   Uchida, Shunya ^d   Fujimori, Shin ^d   Yamamoto, Tetsuya ^e   Hara, Shigeko ^f  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Suzuka Kaisei Hospital   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

^f TORANOMON HOSPITAL   (Japan)

Author keywords

CKD; FYX 051; Gout; Hyperuricemia; Topiroxostat

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; PLACEBO; TOPIROXOSTAT; URIC ACID; ENZYME INHIBITOR; FYX-051; NITRILE; PYRIDINE DERIVATIVE; XANTHINE OXIDASE;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STUDY DESIGN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URINARY EXCRETION; ALBUMINURIA; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; DRUG EFFECTS; MIDDLE AGED; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; URINE;

ADIPONECTIN; AGED; ALBUMINURIA; BLOOD PRESSURE; COMORBIDITY; CREATININE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; GOUT; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; NITRILES; PREVALENCE; PYRIDINES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; URIC ACID; XANTHINE OXIDASE;

EID: 84919848206     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-0935-8     Document Type: Article

References (26)

1. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med. 2012;125:679–87.
2. Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–7.
3. Chonchol M, Shlipak MG, Katz R, Sarnak M, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239–47.
4. Chang HY, Tung CW, Lee PH, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci. 2010;339:509–15.
5. Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30:1018–29.
6. Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202:11–7.
7. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–7.
8. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737–42.
9. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens. 2009;18:526–30.
10. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.
11. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.
12. Collins AJ, Foley RN, Chavers B et al. ‘United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis. 2012; 59(1 Suppl 1):A7, e1–420.
13. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003;278:1848–55.
14. Okamoto K, Matsumoto K, Hille R, et al. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci USA. 2004;101:7931–6.
15. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthr Care Res (Hoboken). 2012;64:1431–46.
16. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337–43.
17. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol. 1987;26:445–9.
18. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.
19. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646–50.
20. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthr Rheum. 2008;59:1540–8.
21. Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthr Rheum. 2012;42:166–78.
22. Sato T, Ashizawa N, Matsumoto K, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051—a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia (corrected). Bioorg Med Chem Lett. 2009;19:6225–9.
23. Matsumoto K, Okamoto K, Ashizawa N, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011;336:95–103.
24. Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol. 2009;297:F481–8.
25. Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16:549–56.
26. Ng WY, Lui KF, Thai AC. Evaluation of a rapid screening test for microalbuminuria with a spot measurement of urine albumin-creatinine ratio. Ann Acad Med Singap. 2000;29:62–5.